The funding round includes participation from Calculus Capital and the North East Venture Fund.
"Notify has become the challenger brand in Safety Tech through our approach to service and innovation, delivered by a fantastic team. I’m delighted we’ve been able to raise additional capital from long term investors to support our latest innovations and to continue our growth trajectory. Thousands of organisations are recognising the value of looking after the health, safety and wellbeing of their workforce, and Notify is now perfectly placed to deliver software that drives employee engagement and productivity."
Lifted Ventures participated in the latest funding round to back the digital health platform.
"Women’s healthcare has been underserved for far too long, and we’re on a mission to change that. At Anya, we combine cutting-edge AI with healthcare specialist support to provide women with the support they need to access the health information they need, whenever they need it in a way that suits them. With the backing of Lifted Ventures and other strategic partners, we’re excited to accelerate our global expansion and continue making a big difference in women’s lives ."
Redalpine led the pre-seed round to help the startup bring its wearable hormone sensors to market and expand its team.
"We did it for blood pressure and will do it again for hormones. Continuous hormone measurement is one of the holy grails of diagnostics, and as fundamental science transitions to engineering, we couldn’t be more excited to back Level Zero Health in their mission to transform hormone tracking with their novel biosensor – paving the way for a new era of personalized health management."
Eos Advisory led the Series A round alongside new and existing backers to fund international expansion and commercialisation.
"The Dxcover technology combines deep technical innovation with machine learning to radically change the diagnostic landscape. Over the last three years they have conclusively shown the accuracy and ease of use of their diagnostic test across multiple cancer indications. This is very much aligned with Eos’ approach to investing in innovation that has the potential to impact positively in people's lives. More recently the team at Dxcover have focused on building a world class international team on both sides of the Atlantic. This funding round is very much about commercialization in both the UK and the US."
Cedars-Sinai and Oxford Science Enterprises backed the seed round to support expansion into the American market.
"The research produced at Oxford is of the highest caliber. An ongoing relationship with OSE will serve our patients and also strengthen the academic and clinical missions of Cedars-Sinai."
— Shlomo Melmed, executive vice president of Medicine & Health Sciences and dean of the Medical Faculty
